
Gaza Humanitarian Foundation
Aid finally started flowing into Gaza last week, ending a three-month blockade by Israel. In charge of aid operations was the newly created Gaza Humanitarian Foundation (GHF), a Swiss-based entity backed by the U.S and Israel.
The GHF has started distributing aid in Gaza via four centralised distribution centres, and said it will open more hubs within a month. Aid will be delivered to the centres via armoured tanks operated by private subcontractors, who will also safeguard its operations. The BBC has noted the presence of Israeli soldiers near the distribution centres.
The GHF aimed to reach one million people at the end of its first week of operations. Three of its sites are in the Rafah area in southern Gaza. A fourth camp is close to the Netzarim corridor in Central Gaza, controlled by the Israeli military. None of the sites are in the north, the region mainly targeted by Israel's strikes. Thousands have reportedly crossed Israeli military lines to access the aid sites. A GHF spokesperson said on May 30 that the Foundation had already distributed 2 million meals. However, only one site was reportedly active, and shut down after it ran out of supplies.
Eyewitness accounts say aid packages have consisted of canned food, pasta, rice, cooking oil, biscuits and lentils. The GHF has said it will distribute meals with 1,750 calories- below the 2,100-calorie per day standard for meals used by UN agencies in emergency situations. A GHF document has reportedly promised to hand out water and hygiene kits at the sites as well.
As per a New York Times report, the GHF resulted from 'private meetings of like-minded officials, military officers and businesspeople with close ties to the Israeli government'. Until his resignation last Sunday, it was run by Jake Wood, a U.S military veteran who also headed a relief group called Team Rubicon, and consists of a group of American security contractors, army veterans and aid workers.
It is unclear who is now in charge, and funding streams remain vague, with the U.S and Israel both denying financial backing. An AP report noted that the GHF claims that an unnamed government in the EU has committed around $100 million.
The GHF aims to sidestep the UN as the main provider of aid to the devastated region. Earlier, Mr. Wood said parallel aid from the UN would continue till eight GHF hubs are established, and that non-humanitarian aid would also be distributed by the UN network. UN agencies had been moving food, medicine and other supplies across Gaza since the war began in October 2023, operating 400 distribution sites for aid before they were blocked by Israel.
About a week back, Israel opened up the border to allow a small inflow of supplies, indicating that the UN would be able to distribute the supplies till the GHF was up and running.
The initial operations of the GHF were further complicated by Palestinian civilians overrunning the aid distribution centre after it opened on Tuesday, resulting in injuries and at least three deaths.
Hunger on the rise
Hunger and desperation are on the rise in Gaza. The Integrated Food Security Phase Classification, a multi-partner initiative focused on analysing nutrition and improving food security, warned in March last year that Gaza was facing a famine. UN estimates say that almost 2 million Gazans are on the brink of starvation; the WHO warned that hunger in Gaza threatened to permanently stunt the growth and cognitive development of an entire generation of children.
The GHF said in a statement it is apolitical and that it won't displace Palestinians. However, it has been condemned by the UN and other aid agencies, which say that the mechanism would allow Israel to use food as a weapon, and that it violates humanitarian principles.
Palestinians have also alleged that the aid effort by the GHF was disorganised, and was hampered by a lack of communication. Misinformation also proliferated on social media about the aid sites, claiming that looting had taken place or that centres were shut down. Further criticisms emerged after videos showed Palestinians running away from the perimeter of one of the aid centres to escape a projectile thrown by the security contractors. The GHF said in a statement that its personnel had 'encountered a tense and potentially dangerous crowd that refused to disperse' and had used 'non-lethal deterrents' to 'prevent escalation and ensure the safety of civilians and staff'.
Israel has mooted for an alternative aid distribution system to avoid what it claims is theft by Hamas from the existing aid networks. Aid convoys of the UN have previously been attacked by Israel. Some of these strikes have killed aid workers as well.
Hamas, meanwhile, has denied looting allegations. The Hamas-run interior ministry has warned Palestinians to be cautious while dealing with the GHF.
In mid-2024, the U.S. built a humanitarian pier off Gaza to enable aid access to the strip, but Palestinians suspected that it would be used for military purposes. Rights organisations pointed out that this was eyewash to obfuscate Israel preventing all land crossings, even for aid. At one point, aid supplies were air-dropped to the war-torn region, a solution considered both dehumanising and ineffective by rights organisations
The UN Relief and Works Agency, the primary aid organisation working to help Palestinians, has been undermined and hobbled.
It has been targeted by misinformation and faced a withdrawal of funds and a ban imposed by Israel's Parliament. A former UNRWA representative called the GHF initiative 'aid-washing', meant to mask the starvation of Palestinians.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
3 hours ago
- Time of India
Sanofi buys US biopharma group Blueprint in $9.1 billion deal
French pharma group Sanofi has agreed to buy US-based Blueprint Medicines Corporation , a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, the companies said on Monday. Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash, representing an equity value of approximately $9.1 billion. The acquisition "represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company," said Sanofi CEO Paul Hudson. The deal will add to Sanofi's portfolio the rare immunology disease drug Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU, and a promising advanced and early-stage immunology pipeline . Blueprint's established presence among allergists, dermatologists, and immunologists is also expected to enhance Sanofi's growing immunology pipeline, the companies said. Live Events Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis, a rare immunology disease, which is characterized by the accumulation and activation of aberrant mast cells in bone marrow, skin, the gastrointestinal tract, and other organs. The acquisition will also bring elenestinib, a next-generation medicine for systemic mastocytosis, as well as BLU-808, a highly selective and potent oral wild-type KIT inhibitor that has the potential to treat a broad range of diseases in immunology. Besides $129.00 per share in cash at the closing of the deal, Blueprint shareholders will also receive one non-tradeable contingent value right (CVR) which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis. Hudson said the deal complements recent acquisitions of other early-stage medicines that remain Sanofi's main field of interest and added that Sanofi still retains a sizeable capacity for further acquisitions.


Time of India
6 hours ago
- Time of India
UAE Health Ministry ends birth and death certification service: What you need to know
In a sweeping administrative change, the UAE Ministry of Health and Prevention (MoHAP) has officially ended its role in issuing birth and death certificates. These vital registration services are now handled by Emirates Health Services (EHS) in the northern emirates, while Dubai and Abu Dhabi continue under their respective local health authorities. Tired of too many ads? go ad free now The transition was made quietly, with MoHAP removing all related service options from its website and discontinuing its WhatsApp-based application system. Residents are now required to navigate a decentralised process based on their emirate of residence. What Has Changed? MoHAP has withdrawn from issuing birth and death certificates. Emirates Health Services (EHS) is now responsible in Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah, and Fujairah. Dubai Health Authority (DHA) and Abu Dhabi's Department of Health (DoH) continue to manage services locally. (DHA) and Abu Dhabi's Department of Health (DoH) continue to manage services locally. Certificates issued by EHS, DHA, or DoH are fully equivalent to those formerly issued by MoHAP. BIRTH CERTIFICATES: How It Works Now Who Can Apply? Parents (of any nationality), legal guardians, or authorised delegates. Where to Apply? Via the EHS website (requires UAE Pass) Through the Mabrouk Ma Yak platform (for Emiratis only) At EHS public health centres or hospitals Documents Needed: Valid Emirates ID and passport for both parents Hospital-issued, certified birth notification Electronic civil record Marriage certificate or notarised parentage document For UAE citizens with births abroad: Return tickets ID and passports of both parents Attested marriage certificate For complex cases (e.g., prison births): Court-issued documents Letters from correctional facilities or social services Birth notifications Fees & Turnaround (Converted to INR) Birth Certificate in Arabic: AED 65 (~₹1,470) English Copy (optional): AED 65 (~₹1,470) Time to Issue: 1 working day DEATH CERTIFICATES: Procedure and Conditions Who Can Apply? Immediate family members or legally authorised persons. Where to Apply? Through the EHS online portal At a designated public health centre or hospital Documents Required: Emirates ID or passport of the deceased No Objection Certificate (NOC) from Ministry of Interior Official death report In suspicious or unknown-cause deaths: Forensic report Name consistency across all documents is mandatory International Use: Certificates must be attested by the UAE Ministry of Foreign Affairs and International Cooperation and the embassy of the relevant foreign country. Fees & Timelines (Converted to INR) Death Certificate in Arabic: AED 65 (~₹1,470) English Copy (optional): AED 65 (~₹1,470) Time to Issue: 5 minutes for e-certificates Physical copy available upon in-person visit Service Hours Monday to Thursday: 7:30 AM to 3:30 PM Friday: 7:30 AM to 12:00 PM Why the Change Matters The UAE is continuing its trend of devolving administrative authority to regional bodies, particularly for citizen services. Emirates Health Services already manages most public healthcare in the northern emirates, making it a natural successor to MoHAP in handling life-event documentation. The Bottom Line The next time you need a birth or death certificate in the UAE, MoHAP is no longer your go-to authority. Depending on where you live, you'll be interacting with EHS, DHA, or DoH—with new procedures, slightly altered fees, and a greater push toward digital verification. While the transition might be procedural, it signals a larger shift in how civil documentation is administered across the UAE—more digital, more localised, and firmly tied to regional health systems. (Exchange rate used: 1 AED = ₹22.60)


Mint
6 hours ago
- Mint
KKR, TPG eye Relisys Medical Devices in early-stage buyout talks
MUMBAI : Relisys Medical Devices is in early-stage discussions with global private equity firms KKR and TPG for a potential ₹1,200–1,300 crore investment, with the transaction likely to offer a full or partial exit to existing investor Siguler Guff, two people familiar with the matter told Mint. 'While TPG is evaluating the company to strengthen its portfolio, KKR is in discussions with the medical devices maker to build out its med-tech platform under which it acquired Healthium Medtech last year from Apax Funds," one of the people cited above said. TPG, too, may look at developing a med-tech platform of its own, the person added. A majority of the proceeds from the transaction, if it materialises, will likely be secondary in nature, enabling Siguler Guff to partially or fully exit. A smaller primary infusion may also be included to fund Relisys's expansion plans, said the second person. Both private equity firms are expected to seek a controlling stake in the Hyderabad-based medical devices maker. In secondary deals, existing shareholders sell their stakes to other investors and the company doesn't receive any new capital. Such shares are usually traded at a discount to primary equity. While KKR declined to comment, TPG, Siguler Guff, Healthium, and Relisys did not respond to Mint's mails sent on Sunday. Also read: Zydus bets big on vaccines and medtech In February, VCCircle had reported that o3 Capital, a mid-market investment bank, was advising Relisys in its search for potential buyers. The report also noted that existing investor Siguler Guff was exploring a full or partial exit, alongside the company's founders, in a transaction then estimated to be valued at $50–70 million ( ₹435–610 crore). Company background Founded in 1997 by technocrats and clinicians, Relisys Medical Devices manufactures cardiovascular products like drug-eluting stents, balloon catheters, diagnostic catheters, and transcatheter heart valves. It also acquired Multimedics in 2018 to expand its stent-making capabilities globally. In FY24, the company reported revenue of ₹169.4 crore, up slightly from ₹162.7 crore a year earlier. Net profit rose marginally to ₹36.3 crore, according to data from Tracxn. The bustling deal activity in the sector also underscores the growing investor appetite for med-tech companies in India. Some notable transactions include Meril Life Sciences $210 million funding from Warburg Pincus which also invested about $300 million in Appasamy Associates. SMT raised $150 million from Samara Capital while Translumina raised around $90 million from Everstone Capital. Also read: Health ministry to set up a panel to review medical device-related adverse events Sector outlook India's $12 billion med-tech market is projected to hit $50 billion by 2030, according to EY. Despite $3.8 billion in exports last fiscal, the country is still heavily import-dependent, with imports at $8.2 billion, making up 80–85% of domestic consumption. Growth is expected to be driven by rising income levels, wider insurance coverage, medical tourism, and rapid healthcare infrastructure expansion in Tier 2 and 3 cities. EY noted that global MNCs are increasingly choosing India for R&D, manufacturing, and global capability centers (GCCs)—further strengthening the ecosystem. Also read: India eyes global pharma dominance with a ₹5,000 crore revitalisation plan